1. Walther D J, et al., Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science, 2003. 299(5603), 76, {Link}
2. Bard J A, et al., Cloning of a novel human serotonin receptor (5-HT7) positively linked to adenylate cyclase. J Biol Chem, 1993. 268(31), 23422-23426, {Link}
3. Lovenberg T W, et al., A novel adenylyl cyclase-activating serotonin receptor (5-HT7) implicated in the regulation of mammalian circadian rhythms. Neuron, 1993. 11(3), 449-458, {Link}
4. Ruat M, et al., Molecular cloning, characterization, and localization of a high-affinity serotonin receptor (5-HT7) activating cAMP formation. Proc Natl Acad Sci U S A, 1993. 90(18), 8547-8551, {Link}
5. Hedlund P B and J G Sutcliffe, Functional, molecular and pharmacological advances in 5-HT7 receptor research. Trends Pharmacol Sci, 2004. 25(9), 481-486, {Link}
6. Yaakob N S, et al., Distribution of 5-HT3, 5-HT4, and 5-HT7 Receptors Along the Human Colon. J Neurogastroenterol Motil, 2015. 21(3), 361-369, {Link}
7. Quintero-Villegas A and S I Valdes-Ferrer, Role of 5-HT7 receptors in the immune system in health and disease. Mol Med, 2019. 26(1), 2, {Link}
8. Brenchat A, et al., Pharmacological activation of 5-HT7 receptors reduces nerve injury-induced mechanical and thermal hypersensitivity. Pain, 2010. 149(3), 483-494, {Link}
9. Nikiforuk A, Targeting the Serotonin 5-HT7 Receptor in the Search for Treatments for CNS Disorders: Rationale and Progress to Date. CNS Drugs, 2015. 29(4), 265-275, {Link}
10. Zareifopoulos N and C Papatheodoropoulos, Effects of 5-HT-7 receptor ligands on memory and cognition. Neurobiol Learn Mem, 2016. 136, 204-209, {Link}
11. Heidmann D E, et al., Four 5-hydroxytryptamine7 (5-HT7) receptor isoforms in human and rat produced by alternative splicing: species differences due to altered intron-exon organization. J Neurochem, 1997. 68(4), 1372-1381, {Link}
12. Krobert K A, et al., The cloned human 5-HT7 receptor splice variants: a comparative characterization of their pharmacology, function and distribution. Naunyn Schmiedebergs Arch Pharmacol, 2001. 363(6), 620-632, {Link}
13. Guthrie C R, et al., Differential agonist-mediated internalization of the human 5-hydroxytryptamine 7 receptor isoforms. J Pharmacol Exp Ther, 2005. 313(3), 1003-1010, {Link}
14. Blattner K M, et al., Pharmacology and Therapeutic Potential of the 5-HT7 Receptor. ACS Chem Neurosci, 2019. 10(1), 89-119, {Link}
15. Deau E, et al., Rational Design, Pharmacomodulation, and Synthesis of Dual 5-Hydroxytryptamine 7 (5-HT7)/5-Hydroxytryptamine 2A (5-HT2A) Receptor Antagonists and Evaluation by [(18)F]-PET Imaging in a Primate Brain. J Med Chem, 2015. 58(20), 8066-8096, {Link}
16. Lundstrom K, Latest development in drug discovery on G protein-coupled receptors. Curr Protein Pept Sci, 2006. 7(5), 465-470, {Link}
17. Pierce K L, et al., Seven-transmembrane receptors. Nat Rev Mol Cell Biol, 2002. 3(9), 639-650, {Link}
18. El Khamlichi C, et al., Serodolin, a beta-arrestin-biased ligand of 5-HT7 receptor, attenuates pain-related behaviors. Proc Natl Acad Sci U S A, 2022. 119(21), e2118847119, {Link}
19. Hogendorf A S, et al., Fluorinated indole-imidazole conjugates: Selective orally bioavailable 5-HT(7) receptor low-basicity agonists, potential neuropathic painkillers. Eur J Med Chem, 2019. 170, 261-275, {Link}
20. MacKinnon A C, et al., Bombesin and substance P analogues differentially regulate G-protein coupling to the bombesin receptor. Direct evidence for biased agonism. J Biol Chem, 2001. 276(30), 28083-28091, {Link}
21. Kolb P, et al., Community guidelines for GPCR ligand bias: IUPHAR review 32. Br J Pharmacol, 2022. 179(14), 3651-3674, {Link}
22. Kenakin T, Functional selectivity through protean and biased agonism: who steers the ship? Mol Pharmacol, 2007. 72(6), 1393-1401, {Link}
23. Wisler J W, et al., Biased G Protein-Coupled Receptor Signaling: Changing the Paradigm of Drug Discovery. Circulation, 2018. 137(22), 2315-2317, {Link}
24. Lane J R, et al., A kinetic view of GPCR allostery and biased agonism. Nat Chem Biol, 2017. 13(9), 929-937, {Link}
25. Watts S W, et al., beta-arrestin biased signaling is not involved in the hypotensive actions of 5-HT(7) receptor stimulation: use of Serodolin. Pharmacol Res, 2024. 199, 107047, {Link}
26. Crispino M, et al., Role of the Serotonin Receptor 7 in Brain Plasticity: From Development to Disease. Int J Mol Sci, 2020. 21(2), {Link}
27. Lee J, et al., Modulation of Serotonin Receptors in Neurodevelopmental Disorders: Focus on 5-HT7 Receptor. Molecules, 2021. 26(11), {Link}
28. Okubo R, et al., Current Limitations and Candidate Potential of 5-HT7 Receptor Antagonism in Psychiatric Pharmacotherapy. Front Psychiatry, 2021. 12, 623684, {Link}
29. Olusakin J, et al., Implication of 5-HT7 receptor in prefrontal circuit assembly and detrimental emotional effects of SSRIs during development. Neuropsychopharmacology, 2020. 45(13), 2267-2277, {Link}
30. Bijata M, et al., Activation of the 5-HT7 receptor and MMP-9 signaling module in the hippocampal CA1 region is necessary for the development of depressive-like behavior. Cell Rep, 2022. 38(11), 110532, {Link}
31. Watts S W, et al., 5-HT is a potent relaxant in rat superior mesenteric veins. Pharmacol Res Perspect, 2015. 3(1), e00103, {Link}
32. Seitz B M, et al., Reduction in Hindquarter Vascular Resistance Supports 5-HT(7) Receptor Mediated Hypotension. Front Physiol, 2021. 12, 679809, {Link}
33. Davis R P, et al., One-month serotonin infusion results in a prolonged fall in blood pressure in the deoxycorticosterone acetate (DOCA) salt hypertensive rat. ACS Chem Neurosci, 2013. 4(1), 141-148, {Link}
34. Seitz B M, et al., 5-HT causes splanchnic venodilation. Am J Physiol Heart Circ Physiol, 2017. 313(3), H676-H686, {Link}
35. Seitz B M, et al., 5-HT does not lower blood pressure in the 5-HT(7) knockout rat. Physiol Genomics, 2019. 51(7), 302-310, {Link}
36. Kim J J and W I Khan, 5-HT7 receptor signaling: improved therapeutic strategy in gut disorders. Front Behav Neurosci, 2014. 8, 396, {Link}
37. Zou B C, et al., Expression and role of 5-HT7 receptor in brain and intestine in rats with irritable bowel syndrome. Chin Med J (Engl), 2007. 120(23), 2069-2074, {Link}
38. Guseva D, et al., Serotonin 5-HT7 receptor is critically involved in acute and chronic inflammation of the gastrointestinal tract. Inflamm Bowel Dis, 2014. 20(9), 1516-1529, {Link}
39. Kim J J, et al., Targeted inhibition of serotonin type 7 (5-HT7) receptor function modulates immune responses and reduces the severity of intestinal inflammation. J Immunol, 2013. 190(9), 4795-4804, {Link}
40. Arreola R, et al., Immunomodulatory effects mediated by serotonin. J Immunol Res, 2015. 2015, 354957, {Link}
41. Ito M, et al., Brain regulatory T cells suppress astrogliosis and potentiate neurological recovery. Nature, 2019. 565(7738), 246-250, {Link}
42. Leon-Ponte M, et al., Serotonin provides an accessory signal to enhance T-cell activation by signaling through the 5-HT7 receptor. Blood, 2007. 109(8), 3139-3146, {Link}
43. Layunta E, et al., Crosstalk Between Intestinal Serotonergic System and Pattern Recognition Receptors on the Microbiota-Gut-Brain Axis. Front Endocrinol (Lausanne), 2021. 12, 748254, {Link}
44. Del Colle A, et al., Novel aspects of enteric serotonergic signaling in health and brain-gut disease. Am J Physiol Gastrointest Liver Physiol, 2020. 318(1), G130-G143, {Link}
45. Gershon M D and K G Margolis, The gut, its microbiome, and the brain: connections and communications. J Clin Invest, 2021. 131(18), {Link}
46. Hoffman J M and K G Margolis, Building community in the gut: a role for mucosal serotonin. Nat Rev Gastroenterol Hepatol, 2020. 17(1), 6-8, {Link}
47. Jenkins T A, et al., Influence of Tryptophan and Serotonin on Mood and Cognition with a Possible Role of the Gut-Brain Axis. Nutrients, 2016. 8(1), {Link}
48. Israelyan N, et al., Effects of Serotonin and Slow-Release 5-Hydroxytryptophan on Gastrointestinal Motility in a Mouse Model of Depression. Gastroenterology, 2019. 157(2), 507-521 e504, {Link}
49. Deraredj Nadim W, et al., Physical interaction between neurofibromin and serotonin 5-HT6 receptor promotes receptor constitutive activity. Proc Natl Acad Sci U S A, 2016. 113(43), 12310-12315, {Link}
50. Morisset S, et al., High constitutive activity of native H3 receptors regulates histamine neurons in brain. Nature, 2000. 408(6814), 860-864, {Link}
51. Alagille D, et al., Evaluation of [F-18]MNI-709 and [F-18]MNI-711 as potential 5HT(7) PET imaging agents. . J. Labelled Compd. Radiopharm 2014. S309,
52. Badarau E, et al., SAR studies on new bis-aryls 5-HT7 ligands: Synthesis and molecular modeling. Bioorg Med Chem, 2010. 18(5), 1958-1967, {Link}
53. Badarau E, et al., New insights into homopiperazine-based 5-HT1A/5-HT7R ligands: synthesis and biological evaluation. J Enzyme Inhib Med Chem, 2010. 25(3), 301-305, {Link}
54. Badarau E, et al., Benzimidazolone-based serotonin 5-HT1A or 5-HT7R ligands: synthesis and biological evaluation. Bioorg Med Chem Lett, 2009. 19(6), 1600-1603, {Link}
55. Reverchon F, et al., T Lymphocyte Serotonin 5-HT(7) Receptor Is Dysregulated in Natalizumab-Treated Multiple Sclerosis Patients. Biomedicines, 2022. 10(10), {Link}
56. Morisset-Lopez S, et al., Applications of biased ligands of the serotonin 5-ht7 receptor for the treatment of pain, multiple sclerosis and the control of thermoregulation. Patent EUROPE n° 21315045.1, 2021,
57. Matthes S, et al., Tryptophan hydroxylase as novel target for the treatment of depressive disorders. Pharmacology, 2010. 85(2), 95-109, {Link}
58. Matthes S, et al., Targeted Manipulation of Brain Serotonin: RNAi-Mediated Knockdown of Tryptophan Hydroxylase 2 in Rats. ACS Chem Neurosci, 2019. 10(7), 3207-3217, {Link}
59. Bader M, Serotonylation: Serotonin Signaling and Epigenetics. Front Mol Neurosci, 2019. 12, 288, {Link}
60. Specker E, et al., Structure-Based Design of Xanthine-Imidazopyridines and -Imidazothiazoles as Highly Potent and In Vivo Efficacious Tryptophan Hydroxylase Inhibitors. J Med Chem, 2023. 66(21), 14866-14896, {Link}
61. Hogendorf A S, et al., Low-basicity 5-HT(7) Receptor Agonists Synthesized Using the van Leusen Multicomponent Protocol. Sci Rep, 2017. 7(1), 1444, {Link}
62. Latacz G, et al., Search for a 5-CT alternative. In vitro and in vivo evaluation of novel pharmacological tools: 3-(1-alkyl-1H-imidazol-5-yl)-1H-indole-5-carboxamides, low-basicity 5-HT(7) receptor agonists. Medchemcomm, 2018. 9(11), 1882-1890, {Link}
63. Hogendorf A S, et al., 2-Aminoimidazole-based antagonists of the 5-HT(6) receptor – A new concept in aminergic GPCR ligand design. Eur J Med Chem, 2019. 179, 1-15, {Link}
64. Kalinowska-Tluscik J, et al., The effect of the intramolecular C-Hcdots, three dots, centeredO interactions on the conformational preferences of bis-arylsulfones – 5-HT(6) receptor antagonists and beyond. RSC Adv, 2018. 8(33), 18672-18681, {Link}
65. Staron J, et al., Pyrano[2,3,4-cd]indole as a Scaffold for Selective Nonbasic 5-HT(6)R Ligands. ACS Med Chem Lett, 2017. 8(4), 390-394, {Link}